Marker Therapeutics, Inc. (MRKR) vs NextCure, Inc. (NXTC)
A side-by-side comparison of Marker Therapeutics, Inc. and NextCure, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MRKR
Marker Therapeutics, Inc.
$1.04HealthcareDelayed quote: Oct 6, 2026, 11:33 AM EDT
NXTC
NextCure, Inc.
$5.30HealthcareDelayed quote: Oct 6, 2026, 11:32 AM EDT
Total return — MRKR vs NXTC
growth of $100 · dividends reinvested · last 7yMRKR -97.9% (-42.3%/yr)NXTC -97.9% (-42.4%/yr)MRKR compounded faster over this window
MRKR NXTC
MRKR vs NXTC: by the numbers
- •NXTC is the larger company ($19M vs $17M market cap).
- •Both run net losses; NXTC's is the smaller (0.00% vs -706.23% net margin).
Metrics side by side
Valuation
| Metric | MRKR | NXTC |
|---|---|---|
| P/S ratio | 14.06 | N/A |
| P/B ratio | 1.43 | 1.58 |
Profitability
| Metric | MRKR | NXTC |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | -706.23% | 0.00% |
| ROE | -71.57% | -351.86% |
| ROIC | -88.07% | -259.91% |
Growth (annualized)
| Metric | MRKR | NXTC |
|---|---|---|
| Total return CAGR (5Y) | -42.13% | -44.29% |
Frequently asked
- How have MRKR and NXTC total returns compared?
- Over the past 5 years, MRKR delivered -42.13% and NXTC delivered -44.29% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.